Vadodara-based Alembic Pharmaceuticals Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) covering Binimetinib tablets in 15 mg and 45 mg strengths. The approval, announced by the company on 14 November 2026, strengthens its portfolio of generic oncology medicines for the United States market.
According to the company’s regulatory filing, the approved product is therapeutically equivalent to Mektovi tablets, 15 mg, the reference listed drug manufactured by Array BioPharma Inc. The approval enables Alembic to advance its participation in the US market for generic versions of Binimetinib, a medicine used in combination therapies for certain types of cancer.
The development also carries commercial significance because Alembic is eligible for 180 days of generic drug exclusivity for both approved strengths, reflecting its position among the first applicants under the USFDA’s abbreviated drug approval framework.
Binimetinib Used in Targeted Cancer Treatment
Binimetinib is a kinase inhibitor used in combination with encorafenib to treat patients with specific forms of cancer associated with mutations in the BRAF gene. The combination is indicated for patients with unresectable or metastatic melanoma carrying a BRAF V600E or V600K mutation.
The combination is also indicated for adult patients with metastatic non-small-cell lung cancer carrying a BRAF V600E mutation. These indications form part of targeted cancer treatment approaches in which medicines are selected according to particular molecular characteristics of the disease.
Binimetinib inhibits MEK1 and MEK2, enzymes involved in cellular signalling pathways that regulate cell growth and survival. Abnormal activation of these pathways can contribute to the development and progression of certain cancers. When administered with encorafenib, which inhibits mutant BRAF proteins, Binimetinib forms part of a combination treatment intended to interfere with the signalling processes supporting cancer cell growth.
Alembic’s USFDA approval relates to the generic formulation of Binimetinib and its therapeutic equivalence to the reference product. It does not represent the approval of a new cancer treatment mechanism but adds an approved generic product to the company’s oncology portfolio.
Alembic Eligible for 180 Days of Generic Drug Exclusivity
A significant aspect of the approval is Alembic’s eligibility for 180 days of generic drug exclusivity in the United States. The company stated that it was one of the first applicants to submit a substantially complete ANDA with a Paragraph IV certification for Binimetinib tablets in the 15 mg strength.
For the 45 mg strength, Alembic was the sole first applicant to submit a substantially complete application with a Paragraph IV certification. Consequently, the company has become eligible for the 180-day generic exclusivity benefit for both strengths.
Under the US pharmaceutical regulatory framework, Paragraph IV certifications are associated with applications challenging patents listed for reference medicines. Eligible first applicants may qualify for a period of generic marketing exclusivity, subject to the relevant statutory and regulatory requirements.
The exclusivity provision is commercially important because it can provide qualifying generic manufacturers with an advantage during the initial phase of market competition. However, eligibility for exclusivity does not itself establish the date of commercial launch or confirm that the exclusivity period has commenced.
US Market for Binimetinib Estimated at $282 Million
Alembic Pharmaceuticals stated that Binimetinib tablets had an estimated United States market size of US$282 million for the 12 months ending September 2026, according to pharmaceutical market intelligence company IQVIA.
The market estimate provides an indication of the existing commercial demand for Binimetinib tablets in the United States. However, the figure represents the estimated market size for the product category and should not be interpreted as a revenue projection for Alembic.
The approval adds another oncology product to the company’s US generic medicines portfolio, where regulatory clearances are essential for participation in the market. The combination of final regulatory approval and eligibility for generic exclusivity represents an important development in Alembic’s efforts to expand its presence in specialised pharmaceutical segments.
Alembic’s Cumulative USFDA Approvals Reach 248
With the latest approval, Alembic Pharmaceuticals has received a cumulative total of 248 ANDA approvals from the USFDA, comprising 230 final approvals and 18 tentative approvals.
The cumulative approvals reflect the company’s continuing involvement in the development and regulatory registration of generic pharmaceutical products for the American market. Final ANDA approvals establish that the applications have satisfied the applicable regulatory requirements, while tentative approvals generally indicate that the applications meet the relevant scientific standards but cannot yet receive final approval because of patent or exclusivity restrictions.
Alembic Pharmaceuticals is a vertically integrated pharmaceutical company with research, development, manufacturing and marketing operations. Its business includes branded generic medicines in India and generic pharmaceutical products supplied to international markets.
The company operates research and manufacturing facilities that have received approvals from regulatory authorities in several developed markets, including the USFDA. Its international pharmaceutical business forms an important part of its operations, alongside its established presence in the Indian branded generics market.
Strengthening India’s Presence in Specialised Generic Medicines
The latest USFDA approval reflects the continuing participation of Indian pharmaceutical manufacturers in the development and supply of complex and specialised generic medicines for international markets.
Oncology medicines represent an important segment of pharmaceutical research and manufacturing because they involve specialised therapeutic requirements, stringent quality standards and detailed regulatory evaluation. The development of generic versions of targeted cancer medicines requires manufacturers to demonstrate that their products satisfy the relevant standards for pharmaceutical quality and therapeutic equivalence.
Alembic’s approval for Binimetinib tablets adds to the regulatory achievements of Indian pharmaceutical companies in international oncology markets. Its eligibility for 180 days of generic exclusivity also highlights the company’s participation in the competitive regulatory framework governing the introduction of generic medicines in the United States.
The development represents another addition to Alembic Pharmaceuticals’ expanding portfolio of USFDA-approved medicines and reinforces the capabilities of India’s pharmaceutical industry in developing and manufacturing specialised generic treatments for global markets.
You may also like
-
Escorts Kubota Plans New Tractor Manufacturing Plant in Uttar Pradesh with Initial Capacity of 60,000 Units
-
DISA India Inaugurates New Manufacturing Facility in Karnataka, Expands Industrial Equipment Production
-
Bharat Electronics Secures ₹619 Crore in New Orders for Drones, Electro-Optics and Defence Systems
-
Piyush Goyal Visits Egypt to Strengthen Trade and Investment Ties as Bilateral Commerce Reaches $6.5 Billion
-
Ayurveda and Blood Pressure: Lifestyle, Stress and Dietary Discipline